Breaks Categories: News

WednesdayMar 23, 2022 1:55 pm

PsychedelicNewsBreaks – Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Participating, Presenting at Upcoming Investor Conferences

Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, will be represented at three upcoming events: the Scottsdale Capital Event, Planet MicroCap Showcase and H.C. Wainwright Annual Global Life Sciences Conference. Delic CEO and cofounder Matt Stang will present at each event, including providing an outline of the company’s strategic outlook; he  will also be available for one-on-one meetings at each event. Hosted by Capital Event Management, the Scottsdale Capital Event is scheduled for April 22–24, 2022. This event is designed to connect growing companies with premier financiers through meetings and…

Continue Reading

ThursdayMar 17, 2022 11:50 am

PsychedelicNewsBreaks – Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) CEO, Cofounder Featured on the Jesse Tee Show Interview

Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, and company CEO and cofounder Matt Stang were spotlighted during a recent segment of the Jesse Tee Show. During the interview, Stang provided a summary of the journey to his present position with Delic Holdings, noting that he started as an intern with “High Times.” He worked in several positions at the publication, eventually buying out one of the owners. Stang also discussed the therapeutic potential of psychedelic compounds and provided a brief history of Delic. “In 2016, we put ‘High Times’ up…

Continue Reading

WednesdayMar 16, 2022 11:30 am

PsychedelicNewsBreaks – Delic Holdings Corp.’s (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Subsidiary Expands Footprint with Opening of Reno Clinic

Delic Holdings’ (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) subsidiary, Ketamine Wellness Centers (“KWC”), the largest ketamine therapy provider in the U.S., has expanded its presence within the state of Nevada with the opening of its Reno location. According to the announcement, KWC Reno is the second of the company's clinics to open in Nevada within the last 18 months, bringing the total number of KWC clinics to 13 across nine states. The 2,200-square-foot treatment facility will serve local patients while also opening its doors to patients in larger California markets who do not have access to affordable in-state providers. “With…

Continue Reading

WednesdayMar 16, 2022 11:22 am

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Announces Participation in Upcoming Maxim Group Virtual Growth Conference

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM) is planning to participate in the 2022 Virtual Growth Conference. The conference is slated for March 28–30, 2022, from 9 a.m. to 5 p.m. ET. Cybin CEO Doug Drysdale will present at the premier event, which is presented by Maxim Group LLC and hosted by M-Vest. Drysdale’s presentation will be available on demand at 9 a.m. ET on Monday, March 28. An archived version of Drysdale’s webcast will be available on the Company’s investor relations website. To view Drysdale’s presentation, visit https://ibn.fm/b928V To view the full press…

Continue Reading

ThursdayMar 10, 2022 12:54 pm

PsychedelicNewsBreaks – Microdose Psychedelic Insights’ March Conference to Showcase Curated CEOs, Capital Advisors and Investment Luminaries from Around the World

Microdose Psychedelic Insights, the leading guide to the business of psychedelics, will be hosting the upcoming Psychedelic Capital: March 2022 Conference. The event, slated to take place in an entirely virtual format on Thursday March 24, will feature some of the top companies, latest IPOs, newest opportunities and deepest industry insights within the psychedelics sector. As part of a bimonthly conference series that dives deep into psychedelic medicine investment, the event will introduce investors and attendees to a carefully selected group of CEOs, capital advisors and luminaries from around the world. “Over the last 18 months of hosting the Psychedelic…

Continue Reading

ThursdayMar 03, 2022 11:12 am

PsychedelicNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Announces Participation Schedule for March Investor Conferences

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology company aiming to transform the treatment of mental health and addiction disorders, today announced that it will be attending three investor conferences in March. The upcoming events include the 34th Annual Roth Conference, the Oppenheimer & Co. Annual Healthcare Conference and Maxim Group’s Virtual Growth Conference. Members of Mydecine’s management team will be available for one-on-one or small group meetings, which may be scheduled by emailing contact@mydecineinc.com. Investor meetings will focus on the company’s research and development pipeline, patent strategies, as well as clinical trials involving targeted drug candidates and therapeutic…

Continue Reading

WednesdayMar 02, 2022 11:14 am

PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) CEO to Participate in Fireside Chat at Oppenheimer Annual Healthcare Conference

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” has announced that its Chief Executive Officer Doug Drysdale will participate in a fireside chat at the Oppenheimer 32nd Annual Healthcare Conference. Drysdale’s presentation is slated to begin at 8:40 a.m. ET on Wednesday, March 16, 2022. Interested parties should visit https://ibn.fm/4Yog7 to register for the event and access the webcast. An archived version of the webcast will be available on the company’s investor relations website. To view the full press release, visit https://ibn.fm/JiX1x About Cybin Inc. Cybin is a leading ethical biopharmaceutical company working…

Continue Reading

TuesdayMar 01, 2022 12:25 pm

PsychedelicNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Announces Positive Pre-IND Meeting with FDA for Smoking Cessation Study

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology company aiming to transform the treatment of mental health and addiction disorders, today announced a positive meeting with the Food and Drug Administration (“FDA”) regarding the company’s Investigational New Drug (“IND”) and breakthrough therapy status applications. During the meeting, Mydecine reviewed its IND application to administer MYCO-001, in combination with therapy, to humans as part of smoking cessation treatment. Dr. Matthew Johnson of Johns Hopkins University, a leading researcher of drug and substance abuse, will serve as the lead investigator for the multisite study. “The data from John Hopkins University’s ongoing…

Continue Reading

FridayFeb 25, 2022 12:07 pm

PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Enters Agreement for Sale of Cobourg Facility for CAD$16.5M

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) is a life sciences holding company dedicated to building a portfolio of assets and biotech solutions. The company has announced its entry into a firm agreement in connection with the sale of its former Cobourg, Ontario-based cannabis processing facility and the 64.43-acre property on which the facility is located (the “transaction”). In consideration of the purchase of the facility, the purchaser has agreed to pay a cash sum of CAD$16,500,000, including a deposit of CAD$660,000 (the “deposit”). FSD Pharma received the deposit on Feb. 24, 2022, and the transaction, which is subject…

Continue Reading

FridayFeb 18, 2022 11:23 am

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Reports Achievement of Additional Adelia Milestone

Cybin (NEO: CYBN) (NYSE American: CYBN),a biopharmaceutical company focused has announced that subsidiary Adelia Therapeutics Inc. has achieved a milestone outlined in the contribution agreement between Cybin, Cybin Corp., Cybin US Holdings Inc. and previous Adelia shareholders; the milestone was identified as Year 2 Q2 (iii). According to the transaction agreement, 17,239.5 Cybin class B common shares will be issued to Adelia shareholders when relevant milestones have been met; the class B Shares will be exchangeable for common shares in the capital of Cybin at an exchange rate of 10 to 1. Adelia is working on developing medicinal psychedelics with improved…

Continue Reading